INS and Insulin resistance: The potential association between decreased insulin resistance and reduced postprandial lipid dysmetabolism suggests that ezetimibe is the possible drug with regard to the vascular protective effects in such patients due to reduction in both insulin level and postprandial hyperlipidemia.